Categories Navigation

Asset Publisher

null HIV/AIDS Team
Hospital Universitario Mútua Terrassa (Barcelona)


The “HIV/AIDS Team” is a multidisciplinary group that since 2007 is part of the Spanish HIV/AIDS Network, under the leadership of David Dalmau, member of its Executive Committee. The team includes clinicians with extensive experience in HIV care, nurses, one epidemiologist as well as a two biologists.

The main research areas of interest, some of them in collaboration with other national and international teams, are:


  • Cardiovascular risk: clinical, biological and genetic characterization, as well as some surrogate markers (Carotid ultrasound measure and vascular stiffness) to determine cardiovascular risk among HIV patients.
  • Neurocognitive impairment: in collaboration with neuropsychologists and neurologists we are performing studies trying to identify parameters (neurocognitive performance, immunological and genetic parameters, plasma and CSF biomarkers) involved in the major risk of neurocognitive impairment among HIV-infected patients.
  • HIV/HCV co-infection: role of the co-infection on certain comorbidities associated to HIV and identification of virological and immunological parameters of therapeutic response.
  • Chronic immunoactivation studies: identification of the potential role of soluble biomarkers (monocyte activation, CRP, IL,…) and cellular biomarkers (monocyte/macrophage phenotype,…) and their role in certain HIV-associated comorbidities. 

2.Antiretroviral Resistance (AR):

  • Primary and secondary genotypic and phenotypic AR to different drugs.
  • Minority variants studies (Ultra Deep Sequencing)

3.HIV Epidemiological studies, in collaboration with SEISIDA and CORIS:

  • HIV early detection
  • Health professionals training 
  • Quality of life
  • Patient’s empowerment

4.International Cooperation:

  • HIV vertical transmission
  • Training courses for health professionals
  • Neurocognitive impairment studies
  • Comparative studies on HIV-late diagnosis between sub-Saharan and European countries.

Related Assets


David Dalmau
Noemí Alonso
Mireia Cairó
Roser Font
Laura Ibañez
Àngels Jaen
Xavier Martinez-Lacasa

Related Assets

Related Assets


  • HIV-infection, atherosclerosis and the inflammatory pathway: candidate gene study in a Spanish HIV-infected population. 
    Ibáñez L, Velli PS, Font R, Jaén A, Royo J, Irigoyen D, Cairó M, De la Sierra A, Arranz MJ, Gallardo D, Dalmau D.  PLoS One. 2014 Nov 10;9(11):e112279 
  • Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing. 
    Pou C, Noguera-Julian M, Pérez-Álvarez S, García F, Delgado R, Dalmau D, Álvarez-Tejado M, Gonzalez D, Sayada C, Chueca N, Pulido F, Ibáñez L, Rodríguez C, Casadellà M, Santos JR, Ruiz L, Clotet B, Paredes R.  Clin Infect Dis. 2014 Aug 15;59(4):578-88. 
  • HIV-associated neurocognitive disorders. 
    Sanmarti M, Ibáñez L, Huertas S, Badenes D, Dalmau D, Slevin M, Krupinski J, Popa-Wagner A, Jaen A.  J Mol Psychiatry. 2014 Mar 4;2(1):2. 
  • Cognitive complaints in people with human immunodeficiency virus in Spain: prevalence and related variables. 
    Muñoz-Moreno JA, Fuster-Ruiz de Apodaca MJ, Fumaz CR, Ferrer MJ, Molero F, Jaen À, Clotet B, Dalmau D.  Med Clin (Barc). 2014 May 20;142(10):438-44. 
  • Monitoring HIV viral load in resource limited settings: still a matter of debate? 
    Arnedo M, Alonso E, Eisenberg N, Ibáñez L, Ferreyra C, Jaén A, Flevaud L, Khamadi S, Roddy P, Gatell JM, Dalmau D; Busia OR Study Group.  PLoS One. 2012;7(12):e47391. 
  • All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. 
    Hernando V, Perez-Cachafeiro S, Lewden C, Gonzalez J, Segura F, Oteo JA, Rubio R, Dalmau D, Moreno S, Amo JD; CoRIS.  J Hepatol. 2012 Oct;57(4):743-51. 
  • HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. 
    de Mendoza C, Anta L, García F, Pérez-Elías MJ, Gutiérrez F, Llibre JM, Menéndez-Arias L, Dalmau D, Soriano V.  AIDS Rev. 2009 Jan-Mar;11(1):39-51. 
  • Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years. 
    Vidal F, Peraire J, Domingo P, Broch M, Cairó M, Pedrol E, Montero M, Viladés C, Gutiérrez C, Sambeat MA, Fontanet A, Dalmau D, Deig E, Knobel H, Sirvent JJ, Richart C, Veloso S, Saumoy M, López-Dupla M, Olona M, Cadafalch J, Fuster M, Ochoa A, Soler A, Guelar A, González J; Chemokines and Long-Term Nonprogressive HIV01 Infection Study Group.  J Acquir Immune Defic Syndr. 2006 Jan 1;41(1):17-22. 
  • Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. 
    Ochoa de Echagüen A, Arnedo M, Xercavins M, Martinez E, Rosón B, Ribera E, Domingo P, González A, Riera M, Llibre JM, Gatell JM, Dalmau D; Nevirapine, Efavirenz and Abacavir (NEFA) Resistance Substudy Team.  AIDS. 2005 Sep 2;19(13):1385-91. 
  • Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. 
    Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM; Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team.  N Engl J Med. 2003 Sep 11;349(11):1036-46. 

Related Assets